Biotech Analysts Kluska, Kim, Stavropoulos and Biotech Associate Miller, along with Dr. Tamayev, MD, PhD, Board-Certified Allergist and Immunologist discuss Chronic Urticaria and the Phase 2 CSU data for CLDX‘s Barzolvolimab (KIT inhibitor) and the potential of JSPR‘s Briquilimab on an Analyst/Industry conference call to be held on March 21 at 11 am. Webcast Link
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLDX:
- Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
- Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference
- Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Celldex 8.52M share Secondary priced at $47.00
- Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock
